Cancer Drug Parity Act of 2025

Referred to the House Committee on Education and Workforce.

• Introduced in House Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

• Education and Workforce Committee
  House of Representatives

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

• PFIZER INC.
  for PFIZER INC. · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
• ASSOCIATION FOR CLINICAL ONCOLOGY
  for ASSOCIATION FOR CLINICAL ONCOLOGY · Virginia · 3rd Quarter 2026 (July 1 - Sep 30)
• CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
  for HEMATOLOGY ONCOLOGY PHARMACY ASSOCIATION · Wisconsin · 3rd Quarter 2026 (July 1 - Sep 30)
• CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
  for HEMATOLOGY ONCOLOGY PHARMACY ASSOCIATION · Wisconsin · 2nd Quarter 2026 (Apr 1 - June 30)
• ASSOCIATION FOR CLINICAL ONCOLOGY
  for ASSOCIATION FOR CLINICAL ONCOLOGY · Virginia · 2nd Quarter 2026 (Apr 1 - June 30)
• ASSOCIATION FOR CLINICAL ONCOLOGY
  for ASSOCIATION FOR CLINICAL ONCOLOGY · Virginia · 1st Quarter 2026 (Jan 1 - Mar 31)

Bodies those filers lobbied

• HOUSE OF REPRESENTATIVES
  14 filings
• SENATE
  14 filings
• Centers For Medicare and Medicaid Services (CMS)
  3 filings
• Health & Human Services, Dept of (HHS)
  2 filings
• Commerce, Dept of (DOC)
  1 filing
• Food & Drug Administration (FDA)
  1 filing
• Labor, Dept of (DOL)
  1 filing
• Office of Management & Budget (OMB)
  1 filing

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.